Phase i and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzenesulfonates
  • Hepatic Insufficiency
  • Neoplasms
  • Pyridines
  • Renal Insufficiency

abstract

  • We recommend the following empiric sorafenib starting doses by cohort: cohort 1, 400 mg twice a day; cohort 2, 400 mg twice a day; cohort 3, 400 mg twice a day; cohort 4, 200 mg twice a day; cohort 5, 200 mg twice a day; cohort 6, not even 200 mg every third day tolerable; cohort 7, not defined; cohort 8, 200 mg each day; and cohort 9, 200 mg each day.

publication date

  • April 10, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2668705

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.20.0931

PubMed ID

  • 19255312

Additional Document Info

start page

  • 1800

end page

  • 5

volume

  • 27

number

  • 11